Safety, tolerability and efficacy of peginterferon alpha-2a and ribavirin in chronic hepatitis C in clinical practice: The German Open Safety Trial

The combination treatment of peginterferon alpha-2a (PEG-IFN alpha-2a; Pegasys®) plus ribavirin (RBV) is recommended as a standard care for HCV infections. Side effects and aspects of efficacy and safety have to be balanced. This study evaluates clinical practice data on safety and efficacy of HCV t...

Descripción completa

Detalles Bibliográficos
Autores principales: Witthöft, Th, Möller, B, Wiedmann, K H, Mauss, St, Link, R, Lohmeyer, J, Lafrenz, M, Gelbmann, C M, Hüppe, D, Niederau, C, Alshuth, U
Formato: Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2007
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2156112/
https://www.ncbi.nlm.nih.gov/pubmed/17927615
http://dx.doi.org/10.1111/j.1365-2893.2007.00871.x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2156112/
https://www.ncbi.nlm.nih.gov/pubmed/17927615
http://dx.doi.org/10.1111/j.1365-2893.2007.00871.x

Ejemplares similares